RMIT startup Lubdub trialled a gel-free ECG patch that produced data 18 times cleaner than Holter monitors in healthy volunteer testing.
“The flexible sensors make better contact with the skin than those used in traditional Holter monitors,” said Professor Sharath Sriram, RMIT University professor and Lubdub co-founder.
The clinical trial of a gel-free, waterproof wearable ECG patch began this week at Midlands Medical Specialists in Perth, Western Australia.
The prototype, developed by Australian startup Lubdub under license from RMIT University, continuously tracks heart rhythm for up to 14 days. Earlier testing in healthy volunteers found the patch produced data 18 times cleaner than standard Holter monitors, potentially allowing the same clinical workforce to monitor 85 percent more patients before artificial intelligence tools are applied, News-Medical reported.
Cardiovascular disease causes one-third of deaths globally and nearly a quarter in Australia, where the majority of heart failure diagnoses occur during unplanned emergency admissions. Lubdub aims to combine the ECG patch with non-invasive biomarker testing and wearable ultrasound imaging into a single diagnostic platform, addressing fragmentation that delays treatment in metropolitan, rural, and remote settings.

“Despite the high prevalence of cardiovascular disease… early symptoms are often missed,” Sriram said. “Our innovation is about simpler and more effective screening, because prevention is better than cure.” The Heart Foundation selected Lubdub as one of its 10 most promising heart health projects for 2026.
A Small Patch Replaces Bulky Holter Monitors
- A Band-Aid-sized patch replaces the bulky, wired Holter monitor, letting you shower and move normally while your heart rhythm is recorded for two weeks.
- Cleaner signals mean cardiologists spend less time filtering noise and more time diagnosing arrhythmias like atrial fibrillation.
- The trial is the first step toward regulatory approval; the device is not yet commercially available for direct consumer purchase.
Trial Design Targets Real-World Diagnostic Gaps
Patients at Midlands Medical Specialists who are already prescribed a standard Holter monitor will wear the Lubdub prototype simultaneously. This head-to-head comparison inside a functioning cardiology clinic—rather than a controlled lab—tests whether the patch maintains signal fidelity during sleep, exercise, and daily hygiene. The primary endpoints focus on signal-to-noise ratio, patient adherence rates, and concordance of arrhythmia detection between the two devices.
Lubdub’s seed funding round closed in September at $6 million, double the initial $3 million target, backed predominantly by physicians and cardiologists. The capital supports the current trial, pilot manufacturing at RMIT’s Discovery to Device facility, and development of the biomarker and ultrasound modules. RMIT Deputy Vice-Chancellor Research and Innovation, Distinguished Professor Calum Drummond AO, said the licensing agreement demonstrates how university research translates into practical health products.
From Personal Loss to Platform Strategy
Co-founder and Director Nikhilesh Bappoo traced the mission to his father’s heart attack in Perth, where timely specialist care averted tragedy. “Had it happened there, the outcome could have been very different,” Bappoo said, referring to Mauritius, where he grew up.
The experience framed Lubdub’s three-pronged approach: a wearable ECG for rhythm, a non-invasive assay for cardiac biomarkers such as troponin, and a handheld ultrasound for structural imaging—all feeding one software dashboard.
Current pathways often require separate appointments for a Holter monitor, blood draw, and echocardiogram, creating delays that are acute in regions with specialist shortages. Integrating these modalities could shift heart failure detection from emergency presentation to outpatient screening.
Perth Trial Aims to Secure TGA Clearance
The Perth trial generates the clinical evidence required for Therapeutic Goods Administration (TGA) clearance in Australia. Lubdub has not disclosed timelines for FDA 510(k) submission in the United States or CE marking under the EU Medical Device Regulation.
Comparable single-lead wearable patches—such as the Zio by iRhythm and BardyDx by Bardy Diagnostics—have established reimbursement codes (CPT 93228, 93229) in the U.S., suggesting a regulatory pathway exists if non-inferiority to Holter monitoring is proven.
| Feature | Standard Holter Monitor | Lubdub Wearable Patch (Prototype) |
|---|---|---|
| Form Factor | Wired electrodes + belt-worn recorder | Wireless, gel-free, waterproof patch |
| Signal Quality (SNR) | Baseline | 18× cleaner (healthy volunteer data) |
| Patient Activity | No showering; limited exercise | Full daily activity including showering |
| Reporting Workflow | Manual technician scan | Automated noise reduction; 85% throughput gain claimed |
Limitations and Medical Precautions for the Investigational Device
- The patch is investigational; it has not received TGA, FDA, or CE Mark approval for diagnostic use.
- Patients with known skin allergies to medical-grade adhesives should disclose this before enrollment.
- The device detects rhythm abnormalities; it does not replace 12-lead ECG for ischemia localization, nor does it measure blood pressure or oxygen saturation.
- Seek immediate emergency care for chest pain, syncope, acute dyspnea, or stroke symptoms regardless of monitoring status.
The next milestone is completion of the Perth cohort and submission of the clinical evaluation report to the TGA. “The clinical trial will gather evidence to support the technology’s further development and potential regulatory approval,” Sriram told News-Medical.
References
- News-Medical. “Wearable heart monitor moves from lab to clinical trial.” November 2026.
- Medical Xpress. “Wearable heart monitor moves from lab to clinical trial.” November 2026.
- RMIT University. “Wearable heart monitor moves from lab to clinical trial.” November 2026.